ID

31735

Beschreibung

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH); ODM derived from: https://clinicaltrials.gov/show/NCT00760916

Link

https://clinicaltrials.gov/show/NCT00760916

Stichworte

Versionen (1)
  1. 24.09.18 24.09.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

24. September 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Pulmonary Hypertension NCT00760916

Englisch

Eligibility Pulmonary Hypertension NCT00760916

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
between 18 and 70 years of age, inclusive
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
body weight at least 50 kilograms
Beschreibung

Body Weight

Datentyp

boolean

Alias
UMLS CUI [1]
C0005910
pah that is either idiopathic/familial; associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years); associated with collagen vascular disease; associated with hiv.
Beschreibung

Idiopathic pulmonary arterial hypertension | Familial pulmonary arterial hypertension | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt Repaired | Pulmonary arterial hypertension Associated with Collagen-vascular disease | Pulmonary arterial hypertension associated with HIV infection

Datentyp

boolean

Alias
UMLS CUI [1]
C3203102
UMLS CUI [2]
C1701939
UMLS CUI [3,1]
C3698160
UMLS CUI [3,2]
C0205340
UMLS CUI [4,1]
C2973725
UMLS CUI [4,2]
C0332281
UMLS CUI [4,3]
C0262428
UMLS CUI [5]
C3697673
currently receiving an approved endothelin receptor antagonist and/or an approved phosphodiesterase-5 inhibitor for at least 90 days and on a stable dose for at least the last 30 days or not currently receiving approved pah therapy.
Beschreibung

Endothelin receptor antagonist Dose Stable | Phosphodiesterase 5 inhibitor Dose Stable | Therapeutic procedure Absent Pulmonary arterial hypertension

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1134681
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2,1]
C1318700
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [3,1]
C0087111
UMLS CUI [3,2]
C0332197
UMLS CUI [3,3]
C2973725
previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of pah.
Beschreibung

Testing Consistent with Pulmonary arterial hypertension | Catheterization of right heart | Echocardiography

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0039593
UMLS CUI [1,2]
C0332290
UMLS CUI [1,3]
C2973725
UMLS CUI [2]
C0189896
UMLS CUI [3]
C0013516
reliable and cooperative with protocol requirements.
Beschreibung

Protocol Compliance

Datentyp

boolean

Alias
UMLS CUI [1]
C0525058
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
nursing or pregnant.
Beschreibung

Breast Feeding | Pregnancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0006147
UMLS CUI [2]
C0032961
received a prostacyclin within the past 30 days.
Beschreibung

Prostacyclins

Datentyp

boolean

Alias
UMLS CUI [1]
C0205911
pah due to conditions other than noted in the above inclusion criteria.
Beschreibung

Pulmonary arterial hypertension Due to Other medical condition | Exception Inclusion criteria

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2973725
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C3843040
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1512693
history of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease.
Beschreibung

Sleep Apnea Uncontrolled | Renal Insufficiency | Anemia | Heart Disease Left sided | Uncontrolled hypertension | Diffuse Parenchymal Lung Disease

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0037315
UMLS CUI [1,2]
C0205318
UMLS CUI [2]
C1565489
UMLS CUI [3]
C0002871
UMLS CUI [4,1]
C0018799
UMLS CUI [4,2]
C0443246
UMLS CUI [5]
C1868885
UMLS CUI [6]
C0206062
use of an investigational drug within 30 days of baseline
Beschreibung

Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C0013230
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Pulmonary Hypertension NCT00760916

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
between 18 and 70 years of age, inclusive
boolean
C0001779 (UMLS CUI [1])
Body Weight
Item
body weight at least 50 kilograms
boolean
C0005910 (UMLS CUI [1])
Idiopathic pulmonary arterial hypertension | Familial pulmonary arterial hypertension | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt Repaired | Pulmonary arterial hypertension Associated with Collagen-vascular disease | Pulmonary arterial hypertension associated with HIV infection
Item
pah that is either idiopathic/familial; associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years); associated with collagen vascular disease; associated with hiv.
boolean
C3203102 (UMLS CUI [1])
C1701939 (UMLS CUI [2])
C3698160 (UMLS CUI [3,1])
C0205340 (UMLS CUI [3,2])
C2973725 (UMLS CUI [4,1])
C0332281 (UMLS CUI [4,2])
C0262428 (UMLS CUI [4,3])
C3697673 (UMLS CUI [5])
Endothelin receptor antagonist Dose Stable | Phosphodiesterase 5 inhibitor Dose Stable | Therapeutic procedure Absent Pulmonary arterial hypertension
Item
currently receiving an approved endothelin receptor antagonist and/or an approved phosphodiesterase-5 inhibitor for at least 90 days and on a stable dose for at least the last 30 days or not currently receiving approved pah therapy.
boolean
C1134681 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C1318700 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0087111 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C2973725 (UMLS CUI [3,3])
Testing Consistent with Pulmonary arterial hypertension | Catheterization of right heart | Echocardiography
Item
previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of pah.
boolean
C0039593 (UMLS CUI [1,1])
C0332290 (UMLS CUI [1,2])
C2973725 (UMLS CUI [1,3])
C0189896 (UMLS CUI [2])
C0013516 (UMLS CUI [3])
Protocol Compliance
Item
reliable and cooperative with protocol requirements.
boolean
C0525058 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Breast Feeding | Pregnancy
Item
nursing or pregnant.
boolean
C0006147 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
Prostacyclins
Item
received a prostacyclin within the past 30 days.
boolean
C0205911 (UMLS CUI [1])
Pulmonary arterial hypertension Due to Other medical condition | Exception Inclusion criteria
Item
pah due to conditions other than noted in the above inclusion criteria.
boolean
C2973725 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C3843040 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C1512693 (UMLS CUI [2,2])
Sleep Apnea Uncontrolled | Renal Insufficiency | Anemia | Heart Disease Left sided | Uncontrolled hypertension | Diffuse Parenchymal Lung Disease
Item
history of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease.
boolean
C0037315 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C1565489 (UMLS CUI [2])
C0002871 (UMLS CUI [3])
C0018799 (UMLS CUI [4,1])
C0443246 (UMLS CUI [4,2])
C1868885 (UMLS CUI [5])
C0206062 (UMLS CUI [6])
Investigational New Drugs
Item
use of an investigational drug within 30 days of baseline
boolean
C0013230 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video